XNCR – Xencor Inc
Xencor, Inc.XNCR
$8.54Name : Xencor, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $601,744,640.00
EPSttm : -3.58
Xencor, Inc.
$8.54
7.83%$0.62Float Short %
10.72
Margin Of Safety %
Put/Call OI Ratio
0.42
EPS Next Q Diff
-0.05
EPS Last/This Y
0.95
EPS This/Next Y
0.26
Price
8.51
Target Price
30.3
Analyst Recom
1.36
Performance Q
-58.55
Relative Volume
1.81
Beta
1.1
Ticker: XNCR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-12 | XNCR | 13.13 | 0.69 | 0.00 | 93 |
| 2025-03-13 | XNCR | 12.86 | 0.69 | 0.00 | 93 |
| 2025-03-14 | XNCR | 12.75 | 0.69 | 0.00 | 93 |
| 2025-03-17 | XNCR | 12.98 | 0.69 | 0.00 | 93 |
| 2025-03-18 | XNCR | 12.55 | N/A | N/A | 0 |
| 2025-03-19 | XNCR | 13.14 | 0.56 | 0.00 | 106 |
| 2025-03-20 | XNCR | 13.45 | 0.56 | 0.00 | 106 |
| 2025-03-21 | XNCR | 13.23 | 0.56 | 0.00 | 106 |
| 2025-03-24 | XNCR | 12.95 | 0.33 | 0.00 | 114 |
| 2025-03-25 | XNCR | 11.81 | 0.33 | 0.00 | 114 |
| 2025-03-26 | XNCR | 11.06 | 0.31 | 999.99 | 117 |
| 2025-03-27 | XNCR | 11.51 | 0.35 | 999.99 | 120 |
| 2025-03-28 | XNCR | 11.23 | 0.36 | 999.99 | 121 |
| 2025-03-31 | XNCR | 10.63 | 0.36 | 999.99 | 121 |
| 2025-04-01 | XNCR | 9.68 | 0.36 | 999.99 | 121 |
| 2025-04-02 | XNCR | 9.82 | 0.36 | 999.99 | 121 |
| 2025-04-03 | XNCR | 8.9 | 0.36 | 999.99 | 121 |
| 2025-04-04 | XNCR | 8.68 | 0.37 | 999.99 | 122 |
| 2025-04-07 | XNCR | 8.36 | 0.37 | 999.99 | 122 |
| 2025-04-08 | XNCR | 7.67 | 0.42 | 0.00 | 126 |
| 2025-04-09 | XNCR | 8.83 | 0.42 | 0.00 | 126 |
| 2025-04-10 | XNCR | 7.92 | 0.41 | 999.99 | 128 |
| 2025-04-11 | XNCR | 8.53 | 0.42 | 0.00 | 129 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-12 | XNCR | 13.14 | 48.4 | - | -2.63 |
| 2025-03-13 | XNCR | 12.87 | 48.4 | - | -2.63 |
| 2025-03-14 | XNCR | 12.76 | 48.4 | - | -2.63 |
| 2025-03-17 | XNCR | 12.98 | 48.4 | - | -2.63 |
| 2025-03-18 | XNCR | 12.62 | 48.4 | - | -2.63 |
| 2025-03-19 | XNCR | 13.14 | 48.4 | - | -2.63 |
| 2025-03-20 | XNCR | 13.47 | 48.4 | - | -2.63 |
| 2025-03-21 | XNCR | 13.22 | 48.4 | - | -2.63 |
| 2025-03-24 | XNCR | 12.95 | 48.4 | - | -2.63 |
| 2025-03-25 | XNCR | 11.82 | 48.4 | - | -2.63 |
| 2025-03-26 | XNCR | 11.06 | 48.4 | - | -2.63 |
| 2025-03-27 | XNCR | 11.51 | 48.4 | - | -2.63 |
| 2025-03-28 | XNCR | 11.23 | 48.4 | - | -2.63 |
| 2025-03-31 | XNCR | 10.64 | 48.4 | - | -2.63 |
| 2025-04-01 | XNCR | 9.69 | 48.4 | - | -2.63 |
| 2025-04-02 | XNCR | 9.82 | 48.4 | - | -2.63 |
| 2025-04-03 | XNCR | 8.92 | 48.4 | - | -2.63 |
| 2025-04-04 | XNCR | 8.69 | 48.4 | - | -2.63 |
| 2025-04-07 | XNCR | 8.36 | 48.4 | - | -2.63 |
| 2025-04-08 | XNCR | 7.67 | 48.4 | - | -2.63 |
| 2025-04-09 | XNCR | 8.81 | 48.4 | - | -2.63 |
| 2025-04-10 | XNCR | 7.91 | 48.4 | - | -2.63 |
| 2025-04-11 | XNCR | 8.51 | 48.4 | - | -2.63 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-12 | XNCR | -4.14 | 2.52 | 8.48 |
| 2025-03-13 | XNCR | -4.14 | 2.52 | 8.48 |
| 2025-03-14 | XNCR | -4.14 | 2.52 | 8.48 |
| 2025-03-17 | XNCR | -4.14 | 2.53 | 8.48 |
| 2025-03-18 | XNCR | -4.17 | 2.53 | 8.48 |
| 2025-03-19 | XNCR | -4.17 | 2.53 | 8.48 |
| 2025-03-20 | XNCR | -4.17 | 2.53 | 8.48 |
| 2025-03-21 | XNCR | -4.17 | 2.53 | 8.48 |
| 2025-03-24 | XNCR | -4.17 | 2.51 | 8.48 |
| 2025-03-25 | XNCR | -4.17 | 2.51 | 8.48 |
| 2025-03-26 | XNCR | -4.17 | 2.51 | 9.18 |
| 2025-03-27 | XNCR | -4.17 | 2.51 | 9.18 |
| 2025-03-28 | XNCR | -4.17 | 2.51 | 9.18 |
| 2025-03-31 | XNCR | -4.17 | 2.41 | 9.18 |
| 2025-04-01 | XNCR | -4.17 | 2.41 | 9.18 |
| 2025-04-02 | XNCR | -3.86 | 2.41 | 9.18 |
| 2025-04-03 | XNCR | -3.86 | 2.41 | 9.18 |
| 2025-04-04 | XNCR | -3.86 | 2.41 | 9.18 |
| 2025-04-07 | XNCR | -3.86 | 2.43 | 9.18 |
| 2025-04-08 | XNCR | -3.86 | 2.43 | 9.18 |
| 2025-04-09 | XNCR | -3.86 | 2.43 | 9.18 |
| 2025-04-10 | XNCR | -3.86 | 2.43 | 10.72 |
| 2025-04-11 | XNCR | -3.86 | 2.43 | 10.72 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.62
Avg. EPS Est. Current Quarter
-0.57
Avg. EPS Est. Next Quarter
-0.67
Insider Transactions
-3.86
Institutional Transactions
2.43
Beta
1.1
Average Sales Estimate Current Quarter
23
Average Sales Estimate Next Quarter
19
Fair Value
Quality Score
30
Growth Score
38
Sentiment Score
19
Actual DrawDown %
85.4
Max Drawdown 5-Year %
-85.8
Target Price
30.3
P/E
Forward P/E
PEG
P/S
5.45
P/B
0.89
P/Free Cash Flow
EPS
-3.64
Average EPS Est. Cur. Y
-2.63
EPS Next Y. (Est.)
-2.36
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-210.53
Relative Volume
1.81
Return on Equity vs Sector %
-53.9
Return on Equity vs Industry %
-41.1
EPS 1 7Days Diff
0.5
EPS 1 30Days Diff
0.46
EBIT Estimation
Xencor, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 250
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
stock quote shares XNCR – Xencor Inc Stock Price stock today
news today XNCR – Xencor Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch XNCR – Xencor Inc yahoo finance google finance
stock history XNCR – Xencor Inc invest stock market
stock prices XNCR premarket after hours
ticker XNCR fair value insiders trading